Disease · MONDO_0005492
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Test Drug vs Control: Number of Patients Who Needed to Return to Treatment Center | 7 of 127 | 19 of 135 | 262 | NCT02935699 | Trial comparisons |
| Test Drug vs Control: deaths from any cause | 0 of 127 | 0 of 135 | 262 | NCT02935699 | Trial comparisons |
| Test Drug vs Control: serious adverse events | 0 of 127 | 1 of 135 | 262 | NCT02935699 | Trial comparisons |
| Levocetirizine vs Placebo: serious adverse events | 1 of 114 | 0 of 59 | 173 | NCT00619801 | Trial comparisons |
| Miltefosine vs Placebo: serious adverse events | 0 of 50 | 0 of 26 | 76 | NCT01170949 | Trial comparisons |
| AK002 Main Study vs AK002 Extended Dosing: deaths from any cause | 1 of 47 | 0 of 5 | 52 | NCT03436797 | Trial comparisons |
| AK002 Main Study vs AK002 Extended Dosing: serious adverse events | 4 of 47 | 1 of 5 | 52 | NCT03436797 | Trial comparisons |
| Omalizumab 75-375 mg vs Placebo to Omalizumab: serious adverse events | 0 of 27 | 2 of 22 | 49 | NCT00481676 | Trial comparisons |
| Active vs Placebo: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT04853992 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 19 | 0 of 19 | 38 | NCT04853992 | Trial comparisons |
| Test Drug vs Control: deaths from any cause | 0 of 16 | 0 of 17 | 33 | NCT02023164 | Trial comparisons |
| Test Drug vs Control: serious adverse events | 0 of 16 | 0 of 17 | 33 | NCT02023164 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005492/comparisons